US › Healthcare

Aldeyra The (ALDX)

US · Healthcare · Biotechnology

$0.70-5.02%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.5M

EPS

$-0.16

EPS estimate

$-0.11

EPS came in at -0.16 against a street estimate of -0.11 — a miss of 45.5%.

Key statistics

Market cap

$42.2M

Forward P/E

0.0

P/B

2.13

Book value

$0.63

EPS (TTM)

$-0.38

52-week high

$5.93

52-week low

$0.65

50-day MA

$1.32

200-day MA

$2.46

Beta

1.20

Analyst view

Analysts rate Aldeyra The a strong buy (5 buy, 1 hold, 0 sell out of 6) with an average price target of $6.60.

Shareholding

Insiders

3.60%

Institutions

61.52%

Largest institutional holders

Fund	Stake
Knoll Capital Management LP	9.08%
AQR Capital Management LLC	6.22%
Kingdon Capital Management LLC	4.40%
Vanguard Capital Management, LLC	3.92%
D. E. Shaw & Co LP	3.22%
Marshall Wace Asset Management Ltd	2.50%
683 Capital Management LLC	2.49%
Jane Street Group LLC	2.28%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Aldeyra The — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.